13 November 2020
Visiongain has published a new report on Antibacterial Drugs Market Report 2021-2031: Forecasts By Drug Class(B-lactam, Cephalosporin, Quinolones, Carbapenems, Penicillin, Macrolides, Fluoroquinolones, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols and Others), By Prescription Type( OTC Antibacterial Drugs and Prescription based Antibacterial Drugs), By Route of Administration (Oral, Topical, and Parenteral, and Others), By Drug Type (Generic drugs, and Branded drugs) By Indication (Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Complicated Urinary Tract Infections and Others) By End-User(Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Antibacterial Drugs market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Antibacterial Drugs market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Antibacterial Drugs Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Antibacterial Drugs market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Bacterial Diseases
The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water. Direct contact and Indirect contact with infected person. Increasing prevalence of bacterial diseases are creating a huge demand for the antibacterial drugs, and leading the market.
Increasing Therapeutic Advancements in Antibacterial Drugs
Increasing burden of bacterial diseases over the last few years has lead various researchers and manufactures to create new advancements in the antibacterial drugs to increase its effectiveness and adoption of antibacterial drugs for bacterial diseases treatments. New therapeutic advancements in antibacterial drugs have increased the demand of the antibacterial drugs.
Increasing Strategic initiatives in Antibacterial Drugs market
Manufactures present in the market are taking various strategic initiatives in order to increase their revenue generation in the market, strategic initiatives such as mergers & acquisitions, product launches and press conference & event. These strategic initiatives are expected to create various opportunities in antibacterial drugs market.
Top companies (Bayer AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc.,) constitute more than XX% share of the global Antibacterial Drugs market. Other companies profiled in the report include: Adenium Biotech ApS, Allecra Therapeutics GmbH, AstraZeneca, SHIONOGI Co., Ltd., BioVersys AG, Eli Lilly, Merck & Co. and Novartis among others. Some of the key developments are listed below:
• In 2019, Allergan has received FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation for the treatment of complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and ventilator-associated bacterial pneumonia (VABP)/hospital-acquired bacterial pneumonia (HABP). Through this development company will widened their market focused product portfolio.
• In 2019, SHIONOGI Co., Ltd. has approved Fetroja (cefiderocol), which is an antibacterial drug for treatment of patients aged more than 18 years suffering from complicated urinary tract infections (cUTI). The approval will help company to increase its presence in the market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.